Hypertension and Cardiac Failure in its Various Forms

Medical Clinics of North America

Volumn 93, Issue 3, 2009, Pages 665-680

  Gaddam, Krishna K ^a   Verma, Anil ^a   Thompson, Mark ^a   Amin, Rohit ^a   Ventura, Hector ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Diastolic heart failure; Hypertension; Hypertensive heart disease; Left ventricular hypertrophy; Systolic heart failure

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; EPLERENONE; INDAPAMIDE; LISINOPRIL; LOSARTAN; METOPROLOL; NEBIVOLOL; PERINDOPRIL; PLACEBO; SPIRONOLACTONE; VALSARTAN; VASODILATOR AGENT;

ADD ON THERAPY; AGING; ALCOHOL CONSUMPTION; ANTIHYPERTENSIVE THERAPY; APOPTOSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIASTOLIC DYSFUNCTION; DRUG EFFICACY; DYSPNEA; EARLY INTERVENTION; ECHOCARDIOGRAPHY; EDEMA; FATIGUE; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE CELL; HEART MUSCLE COMPLIANCE; HEART PROTECTION; HEART RHYTHM; HEART VENTRICULOGRAPHY; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MONOTHERAPY; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PAROXYSMAL DYSPNEA; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RADIOISOTOPE VENTRICULOGRAPHY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION; TACHYCARDIA; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT REDUCTION;

AGING; ANTIHYPERTENSIVE AGENTS; FEMALE; HEART FAILURE, DIASTOLIC; HEART FAILURE, SYSTOLIC; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; STROKE VOLUME;

EID: 65449146439     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2009.02.005     Document Type: Review

References (84)

1. Levy D., Larson M.G., Vasan R.S., et al. The progression from hypertension to congestive heart failure. JAMA 275 20 (1996) 1557-1562
2. Rosamond W., Flegal K., Furie K., et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117 4 (2008) e25-e146
3. Redfield M.M., Jacobsen S.J., Burnett Jr. J.C., et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289 2 (2003) 194-202
4. Bursi F., Weston S.A., Redfield M.M., et al. Systolic and diastolic heart failure in the community. JAMA 296 18 (2006) 2209-2216
5. Lloyd-Jones D.M., Larson M.G., Leip E.P., et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106 24 (2002) 3068-3072
6. He J., Ogden L.G., Bazzano L.A., et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 161 7 (2001) 996-1002
7. Aurigemma G.P., Gottdiener J.S., Shemanski L., et al. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol 37 4 (2001) 1042-1048
8. Bella J.N., Palmieri V., Roman M.J., et al. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the Strong Heart Study. Circulation 105 16 (2002) 1928-1933
9. Laurent G.J. Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol 252 1 Pt 1 (1987) C1-C9
10. Zile M.R., and Brutsaert D.L. New concepts in diastolic dysfunction and diastolic heart failure: part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 105 11 (2002) 1387-1393
11. Richards A.M., Nicholls M.G., Troughton R.W., et al. Antecedent hypertension and heart failure after myocardial infarction. J Am Coll Cardiol 39 7 (2002) 1182-1188
12. Lewis E.F., Moye L.A., Rouleau J.L., et al. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol 42 8 (2003) 1446-1453
13. Thune J.J., Signorovitch J., Kober L., et al. Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. Hypertension 51 1 (2008) 48-54
14. Moncrieff J., Lindsay M.M., and Dunn F.G. Hypertensive heart disease and fibrosis. Curr Opin Cardiol 19 4 (2004) 326-331
15. Ahmed S.H., Clark L.L., Pennington W.R., et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 113 17 (2006) 2089-2096
16. Frohlich E.D. State of the art lecture. Risk mechanisms in hypertensive heart disease. Hypertension 34 (1999) 782-789
17. Gonzalez A., Susana R., Lopez B., et al. Apoptosis in hypertensive heart disease: a clinical approach. Curr Opin Cardiol 21 (2006) 288-294
18. Vasan R.S., Levy D., et al. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med 156 16 (1996) 1789-1796
19. Mottram P.M., Haluska B., Yuda S., et al. Patients with a hypertensive response to exercise have impaired systolic function without diastolic dysfunction or left ventricular hypertrophy. J Am Coll Cardiol 43 5 (2004) 848-853
20. Baltabaeva A., Marciniak M., Bijnens B., et al. Regional left ventricular deformation and geometry analysis provides insights in myocardial remodelling in mild to moderate hypertension. Eur J Echocardiogr 9 4 (2008) 501-508
21. Aeschbacher B.C., Hutter D., Fuhrer J., et al. Diastolic dysfunction precedes myocardial hypertrophy in the development of hypertension. Am J Hypertens 14 2 (2001) 106-113
22. Sokolow M., and Lyon T.P. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 37 2 (1949) 161-186
23. Casale P.N., Devereux R.B., Kligfield P., et al. Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J Am Coll Cardiol 6 3 (1985) 572-580
24. Casale P.N., Devereux R.B., Kligfield P., et al. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation 75 3 (1987) 565-572
25. Lang R.M., Bierig M., Devereux R.B., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18 12 (2005) 1440-1463
26. Paulus W.J., Tschope C., Sanderson J.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28 20 (2007) 2539-2550
27. Bellenger N.G., Francis J.M., Davies C.L., et al. Establishment and performance of a magnetic resonance cardiac function clinic. J Cardiovasc Magn Reson 2 1 (2000) 15-22
28. Grothues F., Moon J.C., Bellenger N.G., et al. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J 147 2 (2004) 218-223
29. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 11 (2005) 1115-1140
30. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 12 (2005) e154-e235
31. Krishnaswamy P., Lubien E., Clopton P., et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 111 4 (2001) 274-279
32. Levine B.D., Lane L.D., Buckey J.C., et al. Left ventricular pressure-volume and Frank-Starling relations in endurance athletes. Implications for orthostatic tolerance and exercise performance. Circulation 84 3 (1991) 1016-1023
33. Meyer T.E., Kovacs S.J., Ehsani A.A., et al. Long-term caloric restriction ameliorates the decline in diastolic function in humans. J Am Coll Cardiol 47 2 (2006) 398-402
34. Schocken D.D., Benjamin E.J., Fonarow G.C., et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 117 19 (2008) 2544-2565
35. Aronow W.S., Ahn C., Kronzon I., et al. Congestive heart failure, coronary events and atherothrombotic brain infarction in elderly blacks and whites with systemic hypertension and with and without echocardiographic and electrocardiographic evidence of left ventricular hypertrophy. Am J Cardiol 67 4 (1991) 295-299
36. Aronow W.S., and Ahn C. Association of electrocardiographic left ventricular hypertrophy with the incidence of new congestive heart failure. J Am Geriatr Soc 46 10 (1998) 1280-1281
37. Moser M., and Hebert P.R. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 27 5 (1996) 1214-1218
38. Klingbeil A.U., Schneider M., Martus P., et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115 1 (2003) 41-46
39. Schmieder R.E., Martus P., and Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 275 19 (1996) 1507-1513
40. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 9311 (2002) 995-1003
41. Okin P.M., Devereux R.B., Harris K.E., et al. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann Intern Med 147 5 (2007) 311-319
42. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42 6 (2003) 1206-1252
43. Kostis J.B., Davis B.R., Cutler J., et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 278 3 (1997) 212-216
44. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 283 15 (2000) 1967-1975
45. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 288 23 (2002) 2981-2997
46. Davis B.R., Piller L.B., Cutler J.A., et al. Role of diuretics in the prevention of heart failure: the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation 113 18 (2006) 2201-2210
47. Davis B.R., Kostis J.B., Simpson L.M., et al. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation 118 22 (2008) 2259-2267
48. Beckett N.S., Peters R., Fletcher A.E., et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358 18 (2008) 1887-1898
49. Bangalore S., Wild D., Parkar S., et al. Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis. J Am Coll Cardiol 52 13 (2008) 1062-1072
50. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334 21 (1996) 1349-1355
51. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 9146 (1999) 9-13
52. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 9169 (1999) 2001-2007
53. Flather M.D., Shibata M.C., Coats A.J., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 3 (2005) 215-225
54. Ghio S., Magrini G., Serio A., et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J 27 5 (2006) 562-568
55. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 325 5 (1991) 293-302
56. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 10 (1992) 669-677
57. Pfeffer M.A., Swedberg K., Granger C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 327 9386 (2003) 759-766
58. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 10 (1999) 709-717
59. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 14 (2003) 1309-1321
60. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 20 (2003) 1893-1906
61. Kober L., and Torp-Pederson C. Clinical characteristics and mortality of patients screened for entry into the Trandalapril Cardiac Evaluation (TRACE) study. Am J Cardiol 76 (1995) 1-5
62. Cohn J.N., and Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
63. Vasan R.S., Evans J.C., Larson M.G., et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 351 1 (2004) 33-41
64. Calhoun D.A., Nishizaka M.K., Zaman M.A., et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40 6 (2002) 892-896
65. Gaddam K.K., Nishizaka M.K., Pratt-Ubunama M.N., et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 168 11 (2008) 1159-1164
66. Nishizaka M.K., Zaman M.A., and Calhoun D.A. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 16 11 Pt 1 (2003) 925-930
67. Chapman N., Dobson J., Wilson S., et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49 4 (2007) 839-845
68. Dzau V.J., Colucci W.S., Hollenberg N.K., et al. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 63 3 (1981) 645-651
69. Swedberg K., Eneroth P., Kjekshus J., et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 82 5 (1990) 1730-1736
70. Weber K.T., and Villarreal D. Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol 71 3 (1993) 3A-11A
71. Brilla C.G., Funck R.C., and Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 102 12 (2000) 1388-1393
72. Bonow R.O., Dilsizian V., Rosing D.R., et al. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. Circulation 72 4 (1985) 853-864
73. Setaro J.F., Zaret B.L., Schulman D.S., et al. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 66 12 (1990) 981-986
74. Warner Jr. J.G., Metzger D.C., Kitzman D.W., et al. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J Am Coll Cardiol 33 6 (1999) 1567-1572
75. Mottram P.M., Haluska B., Leano R., et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 110 5 (2004) 558-565
76. Ohtani T., Ohta M., Yamamoto K., et al. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol 292 2 (2007) R946-R954
77. Nagata K., Obata K., Xu J., et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 47 4 (2006) 656-664
78. Masson S., Staszewsky L., Annoni G., et al. Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarction. J Card Fail 10 5 (2004) 433-441
79. Shapiro B.P., Owan T.E., Mohammed S., et al. Mineralocorticoid signaling in transition to heart failure with normal ejection fraction. Hypertension 51 2 (2008) 289-295
80. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 9386 (2003) 777-781
81. Cleland J.G., Tendera M., Adamus J., et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27 19 (2006) 2338-2345
82. Janardhanan R., Daley W.L., Naqvi T.Z., et al. Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) trial: evolving the management of diastolic dysfunction in hypertension. Am Heart J 152 2 (2006) 246-252
83. Massie B.M., Carson P.E., McMurray J.J., et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359 23 (2008) 2456-2467
84. Solomon S.D., Janardhanan R., Verma A., et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 369 9579 (2007) 2079-2087